Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|April 27, 2010
Membrane protein insertion in E. coliJijun Yuan, Ross E Dalbey, Andreas Kuhn
Journal of Molecular Biology|December 25, 2007
Mechanism and hydrophobic forces driving membrane protein insertion of subunit II of cytochrome bo 3 oxidaseNil Celebi, Ross E Dalbey, Jijun Yuan
Journal of Bacteriology|October 16, 2007
Isolation of cold-sensitive yidC mutants provides insights into the substrate profile of the YidC insertase and the importance of transmembrane 3 in YidC functionJijun Yuan, Gregory J Phillips, Ross E Dalbey
The Journal of Biological Chemistry|November 27, 2013
Polarity and charge of the periplasmic loop determine the YidC and sec translocase requirement for the M13 procoat lep proteinRaunak Soman, Jijun Yuan, Andreas Kuhn, et al.
FEBS Letters|November 11, 2008
The Pf3 coat protein contacts TM1 and TM3 of YidC during membrane biogenesisChristian Klenner, Jijun Yuan, Ross E Dalbey, et al.
Cellular and Molecular Life Sciences : CMLS|October 14, 2009
Protein transport across and into cell membranes in bacteria and archaeaJijun Yuan, Jessica C Zweers, Jan Maarten van Dijl, et al.
Oncotargets and Therapy|November 18, 2020
Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell TransplantQing Li, Juan Mu, Jijun Yuan, et al.
Frontiers in Oncology|October 4, 2021
Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature ReviewGang Feng, Qing Li, Haibo Zhu, et al.
Hematological Oncology|February 23, 2022
Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burdenJuan Mu, Haobin Deng, Cuicui Lyu, et al.
Frontiers in Immunology|August 23, 2021
Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary DiseaseHaobin Deng, Meijing Liu, Ting Yuan, et al.
Pageof 2